Email this article Genital infections and local medications of complex use (application experiences)
- Authors: Mezhevitinova EA1, Abakarova PR1, Brovkina TV1, Poghosyan S.M1, Khlebkova Y.S1
-
Affiliations:
- ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва
- Issue: Vol 16, No 5 (2014)
- Pages: 43-47
- Section: Articles
- URL: https://journals.rcsi.science/2079-5831/article/view/28370
- ID: 28370
Cite item
Abstract
Lower genital tract infections are one of the most frequent reasons for consulting the gynecologist (bacterial vaginosis - 30-35%, vulvovaginal candidiasis - 20-25%, mixed infections - 15-20%, trichomoniasis - 10%, other infections - 10%). Vulvovaginitis tends to grow regardless of the circumstances, is frequently recurrent, and difficult to treat. In the management of patients with different etiologies of vulvovaginitis it is crucial to choose the therapy method wisely. According to the requirements of the International Expert Council of the Centers for Disease Control and Prevention USA (CDC) when choosing the appropriate drug for treatment, it is recommended to take into account the need for drug effects on microbial associations, preferring the means of the elimination of a wide spectrum of possible pathogens that has both trichomonacistic, bactericidal, fungicidal and inflammatory effects. One of the preparations that meets such requirements, is a combined preparation of local action Neo-Penotran Forte L.
Full Text
##article.viewOnOriginalSite##About the authors
E A Mezhevitinova
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва
Email: e_mezhevitinova@oparina4.ru
д-р мед. наук, вед. науч. сотр. научно-поликлинического отд-ния
P R Abakarova
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва
Email: p_abakarova@oparina4.ru
канд. мед. наук, науч. сотр. научно-поликлинического отд-ния
T V Brovkina
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва
Email: t_brovkina@oparini4.ru
аспирант
Sh M Poghosyan
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва
Email: shaqpoxos@mail.ru
аспирант
Yu S Khlebkova
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва
Email: y_khlebkova@oparina4.ru
аспирант
References
- Reis A.J. Treatment of vaginal infections: Candidiasis, bacterial vaginiosis and trichomonasis. J Am Pharm Assoc 1997; NS37: 563-9.
- Foxman B, Muraglia R, Dietz J.P et al. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Lower Genital Tract Dis 2013; 17 (3): 340-5.
- Wang L, Tong Z, Wang Z et al. Single - center retrospective study of the incidence of, and risk factors for, non-C. albicans invasive candidiasis in hospitalized patients in China. Med Mycology 2014; 52 (2): 115-22.
- Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Management 2014; 10: 95-105.
- Ozturk S, Caliskaner Z, Karaayvaz M et al. Hypersensitivity to aeroallergens in patients with recurrent vulvovaginitis of undetermined etiology. J Obstet Gynaecol Res 2007; 33 (4): 469-500.
- Weissenbacher T.M, Witkin S.S, Gingelmaier A et al. Relationship between recurrent vulvovaginal candidosis and immune mediators in vaginal fluid. Eur J Obstet Gynecol Reprod Biol 2009; 144 (1): 59-63.
- Ramsay S, Aatill N, Shankland G, Winter A. Practical management of recurrent vulvovaginal candidiasis, 2009.
- Европейское руководство по ведению больных с патологическими выделениями из влагалища совместно с ВОЗ, 2011.
- Hill G.B. The microbiology of bacterial vaginosis. Am J Obstet Gynecol 1993; 169: 450.
- Ling Z, Kong J, Liu F et al. Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC Genomics 2010; 11: 488.
- Eschenbach D.A, Davick P.R, Williams B.L et al. Prevalence of hydrogen peroxide - producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 1993; 27: 251.
- Lamont R.F, Sobel J.D, Akins R.A et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG 2011; 118: 533.
- Ефимов Б.А., Тютюнник В.Л. Бактериальный вагиноз: современный взгляд на проблему. РМЖ. 2008; 16 (1): 18.
- Кира Е.Ф., Гайтукиева Р.А., Беженарь В.Ф. и др. Многоцентровое контролируемое рандомизированное сравнительное исследование эффективности и безопасности применения препаратов Полижинакс и Тержинан при лечении неспецифического вагинита. Гинекология. 2009; 11 (1): 13-7.
- Саулева Т. Современные взгляды на этиологию, патогенез, диагностику и лечение бактериального вагиноза как заболевания, передаваемого половым путем. Bicнik морькоi медицини. 2000; 3 (11).
- Krauss-Silva L, Moreira M.E.L et al. A randomised controlled trial of probiotics for the prevention of spontaneous preterm delivery associated with bacterial vaginosis: preliminary results Published online 2011; doi: 10.1186/1745-6215-12-239. Trials. 2011; 12: 239. PMCID: PMC3264514.
- Leppäluoto P.A. Bacterial vaginosis: what is physiological in vaginal bacteriology? An update and opinion. Acta Obstetricia et Gynecologica Scandinavica 2011; 90: 1302-6; doi: 10.1111/j.1600-0412.2011.01279
- Прилепская В.Н., Байрамова Г.Р. Этиопатогенез, диагностика и современные направления в лечении бактериального вагиноза. Рус. мед. журн. 2002; 10 (18): 795-7.
- Анкирская А.С. Неспецифические вагиниты. Медицина для всех. 2000; 2 (17).
- Livengood C, Thomason J, Hill G. Bacterial vaginosis. Diagnostic and pathogenetic findings during topical clindamycin therapy. Am J Obstet Gynecol 1990; 163 (2): 515-20.
- Verboon-Maciolek M.A, Gerards L.J, Stoutenbeek P, van Loon A.M. Congenital infection: diagnostic serology of the mother not always definitive. Ned Tijdschr Geneeskd. 2001. 145 (4): 153-6.
Supplementary files
